BRPI0408093A - derivados de imidazol-4-il-etinil-piridina. - Google Patents

derivados de imidazol-4-il-etinil-piridina.

Info

Publication number
BRPI0408093A
BRPI0408093A BRPI0408093-9A BRPI0408093A BRPI0408093A BR PI0408093 A BRPI0408093 A BR PI0408093A BR PI0408093 A BRPI0408093 A BR PI0408093A BR PI0408093 A BRPI0408093 A BR PI0408093A
Authority
BR
Brazil
Prior art keywords
imidazol
disease
ylethynyl
pyridine derivatives
alkylpyridine
Prior art date
Application number
BRPI0408093-9A
Other languages
English (en)
Inventor
Bernd Buettelmann
Simona Maria Ceccarelli
Georg Jaeschke
Sabine Kolczewski
Richard Hugh Phillip Porter
Eric Vieira
Original Assignee
Hofmann La Roche Ag F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hofmann La Roche Ag F filed Critical Hofmann La Roche Ag F
Publication of BRPI0408093A publication Critical patent/BRPI0408093A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE IMIDAZOL-4-IL-ETINIL-PIRIDINA". A presente invenção refere-se a derivados de 4-¢l-aril-imidazol4-iletinil!-2-alquil-piridina e 4-¢1-heteroaril-imidazol-4-iletinil!-2-alquilpiridina e um sal farmaceuticamente aceitável dos mesmos para o tratamento ou prevenção de disturbios mediados de forma total ou em parte pelo receptor metabotrópico glutamato 5, como por exemplo processos degenerativos agudos, traumáticos ou crónicos do sistema nervoso, tais como a doença de Alzheimer, demencia senil, doença de Parkinson, coréia de Huntington, esclerose lateral amiotrófica e escierose múltipla, doenças psiquiátricas, tais como esquizofrenia e ansiedade, depressão, dor e dependência de drogas.
BRPI0408093-9A 2003-03-10 2004-03-05 derivados de imidazol-4-il-etinil-piridina. BRPI0408093A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03004952 2003-03-10
PCT/EP2004/002276 WO2004080998A1 (en) 2003-03-10 2004-03-05 Imidazol-4-yl-ethynyl-pyridine derivatives

Publications (1)

Publication Number Publication Date
BRPI0408093A true BRPI0408093A (pt) 2006-02-14

Family

ID=32981724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408093-9A BRPI0408093A (pt) 2003-03-10 2004-03-05 derivados de imidazol-4-il-etinil-piridina.

Country Status (31)

Country Link
US (1) US7153874B2 (pt)
EP (1) EP1606277B8 (pt)
JP (1) JP4404896B2 (pt)
KR (1) KR100742019B1 (pt)
CN (1) CN100358889C (pt)
AR (1) AR043501A1 (pt)
AT (1) ATE395345T1 (pt)
AU (1) AU2004220382B2 (pt)
BR (1) BRPI0408093A (pt)
CA (1) CA2516682C (pt)
CL (1) CL2004000449A1 (pt)
CO (1) CO5601027A2 (pt)
DE (1) DE602004013746D1 (pt)
DK (1) DK1606277T3 (pt)
ES (1) ES2305739T3 (pt)
HK (1) HK1089443A1 (pt)
HR (1) HRP20050774A2 (pt)
IL (1) IL170129A (pt)
MX (1) MXPA05009524A (pt)
MY (1) MY135491A (pt)
NO (1) NO20054136L (pt)
NZ (1) NZ541643A (pt)
PA (1) PA8597301A1 (pt)
PE (1) PE20041061A1 (pt)
PL (1) PL1606277T3 (pt)
PT (1) PT1606277E (pt)
RU (1) RU2342383C2 (pt)
SI (1) SI1606277T1 (pt)
TW (1) TWI292318B (pt)
WO (1) WO2004080998A1 (pt)
ZA (1) ZA200506834B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7452909B2 (en) * 2003-09-04 2008-11-18 Hoffman-La Roche Inc. Imidazole derivatives
PL1756086T3 (pl) * 2004-06-01 2008-11-28 Hoffmann La Roche Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5
BRPI0511678A (pt) 2004-06-01 2008-01-08 Hoffmann La Roche piridin-4-il-etinil-imidazóis e pirazóis como antagonistas de receptor de mglu5
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
MY148217A (en) 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8334287B2 (en) * 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8957213B2 (en) 2011-04-26 2015-02-17 Hoffman-La Roche Inc. Ethynyl compounds
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
US10941132B2 (en) 2016-01-05 2021-03-09 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
CN110312718B (zh) 2017-01-10 2023-02-28 拜耳公司 作为害虫防治剂的杂环烯衍生物
MX2019008229A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
WO2021110574A1 (en) * 2019-12-02 2021-06-10 F. Hoffmann-La Roche Ag Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors
CN111416154B (zh) * 2020-05-22 2021-08-06 松山湖材料实验室 高电压锂离子电池电解液硅基吡啶添加剂、电解液及其电池
AU2022251771A1 (en) 2021-03-27 2023-09-21 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives
WO2023089049A2 (en) 2021-11-19 2023-05-25 Syngenta Crop Protection Ag Microbiocidal isonicotinic amide derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
US4882343A (en) * 1987-08-28 1989-11-21 G. D. Searle & Co. Biarylalkylimidazole derivatives as anti-depressants
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
DE69822638T2 (de) 1997-08-14 2005-02-24 F. Hoffmann-La Roche Ag Heterocyclische vinylether zur behandlung neurologischer krankheiten
AU780009B2 (en) 1999-08-31 2005-02-24 Merck Sharp & Dohme Corp. Heterocyclic compounds and methods of use thereof
KR100515549B1 (ko) 2000-12-04 2005-09-20 에프. 호프만-라 로슈 아게 글루타메이트 수용체 길항제로서의 페닐에테닐 또는페닐에티닐 유도체
WO2003053922A2 (en) * 2001-12-19 2003-07-03 Merck & Co., Inc. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5

Also Published As

Publication number Publication date
US7153874B2 (en) 2006-12-26
JP2006519802A (ja) 2006-08-31
AU2004220382A1 (en) 2004-09-23
TWI292318B (en) 2008-01-11
ZA200506834B (en) 2006-05-31
AU2004220382B2 (en) 2007-08-02
RU2005131165A (ru) 2007-04-20
CA2516682C (en) 2010-02-02
JP4404896B2 (ja) 2010-01-27
NO20054136L (no) 2005-09-26
PE20041061A1 (es) 2005-01-22
CA2516682A1 (en) 2004-09-23
RU2342383C2 (ru) 2008-12-27
SI1606277T1 (sl) 2008-08-31
PA8597301A1 (es) 2004-09-16
IL170129A (en) 2013-02-28
MXPA05009524A (es) 2005-10-18
HK1089443A1 (en) 2006-12-01
CN1759111A (zh) 2006-04-12
DK1606277T3 (da) 2008-08-18
PT1606277E (pt) 2008-07-08
AR043501A1 (es) 2005-08-03
ES2305739T3 (es) 2008-11-01
MY135491A (en) 2008-04-30
NO20054136D0 (no) 2005-09-06
CO5601027A2 (es) 2006-01-31
DE602004013746D1 (de) 2008-06-26
KR100742019B1 (ko) 2007-07-23
KR20050109074A (ko) 2005-11-17
CN100358889C (zh) 2008-01-02
PL1606277T3 (pl) 2008-10-31
EP1606277A1 (en) 2005-12-21
EP1606277B8 (en) 2008-10-15
WO2004080998A1 (en) 2004-09-23
ATE395345T1 (de) 2008-05-15
TW200423935A (en) 2004-11-16
US20040229917A1 (en) 2004-11-18
NZ541643A (en) 2008-03-28
HRP20050774A2 (en) 2006-09-30
CL2004000449A1 (es) 2005-01-07
EP1606277B1 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
BRPI0408093A (pt) derivados de imidazol-4-il-etinil-piridina.
NO20025517D0 (no) Triazolderivater
CY1112427T1 (el) Ενωσεις διυδροπυριδινης (dihydropyridine) για νευρο-εκφυλιστικες ασθενειες και ανοια
CL2007001030A1 (es) Compuestos derivados de heterociclilguanidina; y composicion farmaceutica, util para el tratamiento de la enfermedad de alzheimer, demencia senil y demencia asociada a enfermedad de parkinson entre otras.
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
CY1111615T1 (el) Αρυλβινυλαζακυκλοαλκανια και μεθοδοι παρασκευης και χρησεως τους.
GEP20084447B (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TW200635906A (en) Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine
IL198072A0 (en) Substituted pyrazinone derivatives for use as a medicine
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
PT2277528E (pt) Uso de vegf e homólogos para tratar doenças do neurónio
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
BR0111892A (pt) Bis-arilsulfonas
WO2007127393A3 (en) Treatment and screening methods for promoting neurogenesis
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics
TW200728300A (en) Therapeutic agents
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2007135131A8 (en) Substituted pyrazinone derivatives for use as a medicine
IL167848A (en) Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
WO2008092877A3 (en) 8-oxa-1, 4-diazaspiro [4,5] dec-3-en-1-yl and 1,4, 8-triazaspiro [4,5] dec- 3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
WO2009078432A1 (ja) １-アルキル-４-アミノ-１ｈ-ピラゾール-３-カルボキサミド化合物
EA200870452A1 (ru) Производные замещенного пиразинона для применения в качестве лекарственных средств
IL192240A0 (en) Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
WO2008061329A3 (en) PHα1B TOXIN, CDNA OF PHα1 B TOXIN GENE, PHARMACEUTICAL COMPOSITIONS CONTAINING PHα1B TOXIN, PROCESSES FOR THEIR OBTENTION AND PRODUCT
DOP2004000843A (es) Derivados de imidazol-4-il-etinil-piridina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2307 DE 24/03/2015.